CRYOPORT, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
CRYOPORT, INC. (CYRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $0 for the 9-month period ending 2016-12-31, per its 10-KT filed 2017-03-13.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2017-03-13
- CRYOPORT, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for the quarter ending 2015-03-31 was $462.00K.
- CRYOPORT, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for the quarter ending 2014-03-31 was $0.00.
- CRYOPORT, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2016 was $76.00K, a 83.55% decline from fiscal 2015.
- CRYOPORT, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2015 was $462.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|---|---|
| 2016-12-31 | $0.00 10-KT · filed 2017-03-13 | ||
| 2016-03-31 | $76.00K 10-KT · filed 2017-03-13 | ||
| 2015-03-31 | $462.00K 10-K · filed 2015-05-19 | $462.00K 10-K · filed 2016-06-28 | |
| 2014-03-31 | $0.00 10-K · filed 2015-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |